Table 4.
Anti-proliferative effect of somatostatin analogues in patients with progressive disease.
| SSA | Dosagen | n | CR | PR | SD | PD | Reference |
|---|---|---|---|---|---|---|---|
| Lanreotide | 3000 μg/day | 22 | 0 | 1 | 7 | 14 | (93) |
| Lanreotide | 30 mg/2 weeks | 35 | 0 | 1 | 20 | 14 | (91) |
| Octreotide | 600/1500 μg/day | 52 | 0 | 0 | 19 | 33 | (75) |
| Octreotide | 1500/3000 μg/day | 58 | 0 | 2 | 27 | 29 | (28) |
| Lanreotide | 15000 μg/day | 24 | 1 | 1 | 11 | 11 | (93) |
| Octreotide | 600 μg/day | 10 | 0 | 0 | 5 | 5 | (74) |
| Octreotide median dose of 250 μg three times daily | 34 | 0 | 1 | 17 | 0 | (76) | |
| Octreotide-LAR 30/lanreotide SR 60 mg/28 days | 31 | 0 | 0 | 14 | 4 | (77) | |
| Total | 256 | 1 | 6 | 115 | 105 | ||
| Percentage (%) | 0.3 | 2 | 45 | 41 | |||
CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease.